Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...
Introducing Ozempic, a groundbreaking GLP-1 agonist now making waves in India! This innovative treatment emulates a natural ...
Denmark: Novo Nordisk and Akero Therapeutics have announced that Novo Nordisk's acquisition of Akero has been completed.With ...
MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic ...
The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...
Altimmune, Inc. nears key MASH data for pemvidutide—learn investor risks, potential rewards, and what the upcoming results ...
Khaleej Times on MSN
Wegovy shows liver health benefits in MASH patients beyond weight loss
Novo Nordisk’s Wegovy® (semaglutide 2.4 mg) was associated with liver health–related benefits not solely driven by weight ...
This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients.
Novo Nordisk (NYSE:NVO) is one of the most profitable large cap stocks to buy right now. On November 10, Novo Nordisk announced new post hoc analysis data from the ESSENCE Phase 3 trial regarding the ...
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...
Novo Nordisk (NYSE:NVO) is one of the most profitable large cap stocks to buy right now. On November 10, Novo Nordisk announced new post hoc analysis data from the ESSENCE Phase 3 trial regarding the ...
MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic dysfunction-associated steatohepatitis (MASH): Moderator Sobia Laique, MD, of the Cleveland ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback